SCHEMBL13436330

SCHEMBL13436330

CC(C)c1cncc(N2CCN(C(C)C)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
PKM P14618 1/20 0.45
TGFBR1 P36897 2/20 0.41
ACVR1 Q04771 2/20 0.41
KCNH2 Q12809 1/20 0.41
CCR6 P51684 2/20 0.38
KHK P50053 1/20 0.37
HRH3 Q9Y5N1 3/20 0.37
MCOLN2 Q8IZK6 1/20 0.36
CHRNB2 P17787 2/20 0.36
CHRNA4 P43681 2/20 0.36
ALK Q9UM73 1/20 0.35
MET P08581 1/20 0.35
VCP P55072 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13436487 0.94 KDM4E (0.41) KDM4EALDH1A1MAPTPKMTGFBR1
SCHEMBL13436500 0.85 HRH4 (0.44) KDM4EALDH1A1MAPTCCR6
SCHEMBL15871375 0.84 HRH3 (0.39) TGFBR1ACVR1KCNH2CCR6HRH3
SCHEMBL21282988 0.84 CCR6 (0.45) CCR6CHRNB2CHRNA4
SCHEMBL14098553 0.84 CCR6 (0.48) CCR6CHRNB2CHRNA4
SCHEMBL16131144 0.83 CCR6 (0.47) CCR6CHRNB2CHRNA4
SCHEMBL13436326 0.82 CCR6 (0.39) CCR6HRH3CHRNB2CHRNA4
SCHEMBL15345003 0.81 KDM4E (0.46) KDM4EALDH1A1MAPTPKMTGFBR1
SCHEMBL13436331 0.81 KDM4E (0.46) KDM4EALDH1A1MAPTCCR6KHK
SCHEMBL13436267 0.80 CHRNB2 (0.58) CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180127388-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2018-05-10 US disclosed
US-20180127388-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2018-05-10 US disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
WO-2010034838-A2 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127388-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 KDM4E 4221/4885ALDH1A1 355/4885MAPT 1627/4885
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 KDM4E 2715/4885ALDH1A1 175/4885MAPT 3852/4885
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 KDM4E 4221/4885ALDH1A1 355/4885MAPT 1627/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 KDM4E 4221/4885ALDH1A1 355/4885MAPT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.